LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Elenco Azioni・MacroGenics Inc

MacroGenics Inc

Chiusa

SettoreSettore sanitario

3.87 -0.51

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.84

Massimo

4.05

Metriche Chiave
By Trading Economics
Entrata	-23M -37M
Vendite	-20M 21M
EPS	-0.58
Margine di Profitto	-177.011
Dipendenti	293
EBITDA	-17M -32M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+61.89% upside

Dividendi
By Dow Jones
Utili prossimi	12 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	76M 263M
Apertura precedente	4.38
Chiusura precedente	3.87

Notizie sul Sentiment di mercato

By Acuity

50%

161 / 344 Classifica in Healthcare

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 giu 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 giu 2026, 15:41 UTC

I principali Market Mover

American Battery Shares Jump on Energy Department Victory

8 giu 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 giu 2026, 23:37 UTC

Discorsi di Mercato

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 giu 2026, 23:25 UTC

Discorsi di Mercato

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 giu 2026, 23:25 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 giu 2026, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 giu 2026, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Agrees to Buy m3ter

8 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

8 giu 2026, 19:22 UTC

Discorsi di Mercato

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 giu 2026, 19:01 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 giu 2026, 18:52 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

8 giu 2026, 18:52 UTC

Discorsi di Mercato

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 giu 2026, 18:17 UTC

Discorsi di Mercato

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 giu 2026, 17:32 UTC

Discorsi di Mercato

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 giu 2026, 17:29 UTC

Discorsi di Mercato

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 giu 2026, 17:29 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 giu 2026, 16:55 UTC

Acquisizioni, Fusioni, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 giu 2026, 16:54 UTC

Acquisizioni, Fusioni, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 giu 2026, 16:40 UTC

Discorsi di Mercato

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 giu 2026, 16:31 UTC

Discorsi di Mercato

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 giu 2026, 16:27 UTC

Discorsi di Mercato

Mexican Inflation Seen Easing in May -- Market Talk

8 giu 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 giu 2026, 16:03 UTC

Acquisizioni, Fusioni, Takeovers

Orange Bought Stake From Lorca

8 giu 2026, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 giu 2026, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 giu 2026, 15:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 giu 2026, 15:58 UTC

Discorsi di Mercato

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 giu 2026, 15:55 UTC

Discorsi di Mercato

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 giu 2026, 15:41 UTC

Discorsi di Mercato

Gold Falls Below 200-Day Moving Average -- Market Talk

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

61.89% in crescita

Previsioni per 12 mesi

Media 6.33 USD 61.89%

Alto 9 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a MacroGenics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

161 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.